• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Diabetes Drugs and Cardioprotection: A Summary for Primary Care

Slideshow

These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.

Recent study findings—many of which were presented at the recent American Diabetes Association (ADA) 81st Scientific Sessions—have demonstrated cardioprotective effects of sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). In the slides below, find concise summaries of the more significant developments in the use of diabetes drugs for ASCVD prevention.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Semaglutide Linked with Reduced Risk of Alzheimer Disease in Large Observational Study / image credit Rong Xu, PhD Courtesy Case Western Reserve University

Semaglutide Linked with Reduced Risk of Alzheimer Disease in Large Observational Study

Grace Halsey
October 25th 2024
Article

Semaglutide significantly reduced risk of a first-time diagnosis of AD in a cohort of more than 1 million, suggesting an opportunity for controlled clinical trials.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial / image credit heart and kidneys: ©krishnacreations/stock.adobe.com

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

Grace Halsey
October 21st 2024
Article

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Why Are Women Still Missing from Cardiovascular Clinical Trials? image credit ©Chinnapong/stock.adobe.com

Why Are Women Still Missing from Cardiovascular Clinical Trials?

Hayden E. Klein
October 17th 2024
Article

Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List / image credit Mounjaro: ©MK Photo/stock.adobe.com

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List

Ashley Gallagher;Grace Halsey
October 15th 2024
Article

Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.

© 2024 MJH Life Sciences

All rights reserved.